<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g129" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-127.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-47.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-87.html" >Diseases Characterized by Genital, Anal, or Perianal Ulcers</a><span class="carrot"> > </span>
                    <a href="lv-87.html" >Syphilis</a><span class="carrot"> > </span>
                    <a href="lv-127.html" >Syphilis Among HIV-Infected Persons</a><span class="carrot"> > </span>Treatment
            </div>
            </br><h4 class="sgc-1 sgc-1" id="sigil_toc_id_129">
 Treatment
</h4>
<p>
 Compared with HIV-negative patients, HIV-positive patients who have early syphilis might be at increased risk for&nbsp;neurologic complications (224) and might have higher rates of serologic treatment failure with currently recommended regimens. The magnitude of these risks is not defined precisely, but is likely small. No treatment regimens for syphilis have been demonstrated to be more effective in preventing neurosyphilis in HIV-infected patients than the syphilis regimens recommended for HIV-negative patients (208). Careful follow-up after therapy is essential.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

